Detected ·
Oyster Therapeutics
$60MSeries A
Oyster Therapeutics (formerly Kesmalea Therapeutics) raised a $60M Series A-2 led by 4BIO, with new investors Eli Lilly and Company, Actium Group, Crescent Enterprises and TOHO Ventures, alongside existing backers Syncona, Mission BioCapital and Mass General Brigham Ventures, to advance its tau-targeting therapies for Alzheimer's.
- Website
- —
- linkedin.com/company/98348645
- Amount
- $60 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-11 04:04:52 UTC
- Signal ID
- 515cb589-aee3-48db-a642-bed9d4b14540
As the API returns it
{
"id": "515cb589-aee3-48db-a642-bed9d4b14540",
"created_at": "2026-11-11T04:04:52.882935Z",
"company_name": "Oyster Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/98348645",
"event_type": "funding",
"funding_amount": 60000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Oyster Therapeutics (formerly Kesmalea Therapeutics) raised a $60M Series A-2 led by 4BIO, with new investors Eli Lilly and Company, Actium Group, Crescent Enterprises and TOHO Ventures, alongside existing backers Syncona, Mission BioCapital and Mass General Brigham Ventures, to advance its tau-targeting therapies for Alzheimer's.*"
}